Physician profile
Arnold Smith
NPI 1346213311
$2,794.71
in general payments reported to CMS, 2019-2025
43 companies · $200 in 2025
The $200 reported for 2025 was more than what a typical Radiation Oncology provider received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,065 · 2020: $871 · 2021: $35.43 · 2022: $358 · 2023: $139 · 2024: $126 · 2025: $200.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $466.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $466.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $346.41 | 2019-2025 | |
| Amgen INC. | $185.66 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $160.84 | 2019-2023 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $154.18 | 2019-2025 | |
| Medtronic, INC. | $144.76 | 2025 | Kyphon Express II Kyphopak Tray |
| Takeda Pharmaceuticals U.S.A., INC. | $117.97 | 2019-2020 | |
| Palette Life Sciences, INC. | $110.59 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $102.83 | 2019-2024 | Libtayo |
| Novartis Pharmaceuticals Corporation | $101.22 | 2019-2021 | |
| Eisai INC. | $95.87 | 2019-2020 | |
| Elekta, INC. | $89.82 | 2022 | |
| Emd Serono, INC. | $78.49 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $77.18 | 2019-2020 | |
| Celgene Corporation | $72.07 | 2019-2020 | |
| Janssen Biotech, INC. | $63.25 | 2019-2020 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arnold Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.